THE REALITY OF PROPHYLACTIC NIPPLE-SPARING MASTECTOMY IN BRAZIL

Medina-Franco H, Vasconez LO, Fix RJ, Heslin MJ, Beenken SW, Bland KI, et al. Factors associated with local recurrence after skin-sparing mastectomy and immediate breast reconstruction for invasive breast cancer. Ann Surg. 2002;235:814-9.

Carlson GW, Styblo TM, Lyles RH, Jones G, Murray DR, Staley CA, et al. The use of skin-sparing mastectomy in the treatment of breast cancer: The Emory experience. Surg Oncol. 2003;12:265-9.

Uriburu JL, Vuoto HD, Cogorno L, Isetta JA, Candas G, Imach GC, et al. Local recurrence of breast cancer after skin-sparing mastectomy following core needle biopsy: case reports and review of the literature. Breast J. 2006;12:194-8. https://doi.org/10.1111/j.1075-122X.2006.00240.x

Warren PA, Foster RD, Stover AC, Itakura K, Ewing CA, Alvarado M, et al. Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts. Ann Surg Oncol. 2012;19(11):3402-9. https://doi.org/10.1245/s10434-012-2362-y

Rice CO, Strickler JH. Adeno-mammectomy for benign breast lesions. Surg Gynecol Obstet. 1951;93:759-62.

Benediktsson KP, Perbeck L. Survival in breast cancer after nipple-sparing subcutaneous mastectomy and immediate reconstruction with implants: a prospective trial with 13 years median follow-up in 216 patients. Eur J Surg Oncol. 2008;34(2):143-8. https://doi.org/10.1016/j.ejso.2007.06.010

Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340:77-84. https://doi.org/10.1056/NEJM199901143400201

De Felice F, Marchetti C, Musella A, Palaia I, Perniola G, Musio D, et al. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Ann Surg Oncol. 2015;22:2876-80. https://doi.org/10.1245/s10434-015-4532-1

Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg. 2016;212:660-9. https://doi.org/10.1016/j.amjsurg.2016.06.010

Castera L. Krieger S, Rousselin A, Legros A, Baumann JJ, Bruet O, et al. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Human Genet. 2014;22:1305-13. https://doi.org/10.1038/ejhg.2014.16

Silva FC, Lisboa BC, Figueiredo MC, Torrezan GT, Santos EM, Krepischi AC, et al. Hereditary breast and ovarian cancer: assessment of point mutation and copy number variations in Brazilian patients. BMC Med Genet. 2014;15:15:55. https://doi.org/10.1186/1471-2350-15-55

Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet. 2008;124:31-42. https://doi.org/10.1007/s00439-008-0529-1

Lhota F, Zemankova P, Kleiblova P, Soukupova J, Vocka M, Stranecky V, et al. Hereditary truncating mutations of DNA repair and other genes in BRCA1/BRCA2/PALB2 negatively tested breast cancer patients. Clin Genet. 2016;90(4):324-33. https://doi.org/10.1111/cge.12748

Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-71.

Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789-92. https://doi.org/10.1038/378789a0

Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-75. https://doi.org/10.1001/jama.2010.1237

Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33:304-11. https://doi.org/10.1200/JCO.2014.57.1414

National Comprehensive Cancer Network. NCCN Clinical practice guidelines in Oncology [Internet]. Disponível em: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

Evans DGR, Barwell J, Eccles DM, Collins A, Izatt L, Jacobs C, et al. The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res. 2014;16(5):442. https://doi.org/10.1186/s13058-014-0442-6

Yao K, Stewart AK, Winchester DJ, Winchester DP. Trends in contralateral prophylatic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007. Ann Surg Oncol. 2010;17:2554-62. https://doi.org/10.1245/s10434- 010-1091-3

Tuttle T, Jarosek S, Habermann E, Arrington A, Abraham A, Morris TJ, et al. Increasing rates of contralateral prophylatic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009;27(9):1362-7. https://doi.org/10.1200/JCO.2008.20.1681

Ager B, Butow P, Jansen J, Phillips KA, Porter D; CPM DA Advisory Group. Contralateral prophylatic mastectomy (CPM): A systematic review of patient reported factors and psychological predictors influencing choice and satisfaction. The Breast. 2016;28:107-120. https://doi.org/10.1016/j.breast.2016.04.005

Brewster AM, Parker PA. Current knowledge on contralateral prophylatic mastectomy among women with sporadic breast cancer. Oncologist. 2011;16:935-41. https://doi.org/10.1634/theoncologist.2011-0022

Mortenson MM, Schneider PD, Khatri VP, Stevenson TR, Whetzel TP, Sommerhaug EJ, et al. Immediate breast reconstruction after mastectomy increases wound complications: however, initiation of adjuvante chemotherapy is not delayed. Arch Surg. 2004;139:988-91. https://doi.org/10.1001/archsurg.139.9.988

Murphy JA, Milner TD, O’Donoghue JM. Contralateral riskreducing mastectomy in sporadic breast cancer. Lancet Oncol. 2013;14:e262-9. https://doi.org/10.1016/S1470-2045(13)70047-0